A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 3

Conditions

Diphtheria

Tetanus

Acellular Pertussis

Treatments

Biological: Combined diphtheria, tetanus, acellular pertussis vaccine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00109330

776423/001

Details and patient eligibility

About

This study will evaluate the safety and immune response to GlaxoSmithKline Tdap vaccine compared to licensed Td vaccine when used as a booster in healthy adolescents (10-18 years of age).

Full description

A combined Tdap (Tetanus, Diphteria, Acellular Pertussis) Vaccine Used as a Booster compared to Licensed Td (Tetanus and Diphteria) vaccine

Enrollment

4,116 patients

Sex

All

Ages

10 to 18 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Healthy adolescents with history of completed routine vaccination against diphtheria, tetanus, and pertussis (DTP).

Exclusion criteria

Use of any other investigational drug or vaccine 30 days preceding study vaccination.
Chronic administration of immunosuppressants.
Administration of pre-school DTP vaccine within previous 5 years.
Administration of Td booster within previous 10 years.